Focused On-demand Library for Cytochrome b

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Complex III subunit 3; Complex III subunit III; Cytochrome b-c1 complex subunit 3; Ubiquinol-cytochrome-c reductase complex cytochrome b subunit

Alternative UPACC:

P00156; Q34786; Q8HBR6; Q8HNQ0; Q8HNQ1; Q8HNQ9; Q8HNR4; Q8HNR7; Q8W7V8; Q8WCV9; Q8WCY2; Q8WCY7; Q8WCY8; Q9B1A6; Q9B1B6; Q9B1B8; Q9B1D4; Q9B1X6; Q9B2V0; Q9B2V8; Q9B2W0; Q9B2W3; Q9B2W8; Q9B2X1; Q9B2X7; Q9B2X9; Q9B2Y3; Q9B2Z0; Q9B2Z4; Q9T6H6; Q9T9Y0; Q9TEH4


Cytochrome b, known as Complex III subunit 3, plays a pivotal role in the mitochondrial respiratory chain. It facilitates electron transfer from ubiquinol to cytochrome c, contributing to ATP synthesis. This protein's alternative names include Complex III subunit III and Ubiquinol-cytochrome-c reductase complex cytochrome b subunit.

Therapeutic significance:

Cytochrome b's malfunction is linked to diseases such as Cardiomyopathy, infantile histiocytoid, and Leber hereditary optic neuropathy. These associations underscore the protein's potential as a target for therapeutic intervention in mitochondrial and cardiovascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.